Abstract Title:

Cannabis in Palliative Medicine: Improving Care and Reducing Opioid-Related Morbidity.

Abstract Source:

Am J Hosp Palliat Care. 2011 Apr 7. Epub 2011 Apr 7. PMID: 21444324

Abstract Author(s):

Gregory T Carter, Aaron M Flanagan, Mitchell Earleywine, Donald I Abrams, Sunil K Aggarwal, Lester Grinspoon

Article Affiliation:

Hospice Services, Providence Medical Group, Olympia, WA, USA.

Abstract:

Unlike hospice, long-term drug safety is an important issue in palliative medicine. Opioids may produce significant morbidity. Cannabis is a safer alternative with broad applicability for palliative care. Yet the Drug Enforcement Agency (DEA) classifies cannabis as Schedule I (dangerous, without medical uses). Dronabinol, a Schedule III prescription drug, is 100% tetrahydrocannabinol (THC), the most psychoactive ingredient in cannabis. Cannabis contains 20% THC or less but has other therapeutic cannabinoids, all working together to produce therapeutic effects. As palliative medicine grows, so does the need to reclassify cannabis. This article provides an evidence-based overview and comparison of cannabis and opioids. Using this foundation, an argument is made for reclassifying cannabis in the context of improving palliative care and reducing opioid-related morbidity.

Study Type : Review

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.